Optineurin mediates macrophage autophagy, thereby inhibiting the intestinal macrophage-mediated inflammatory response and helping to reduce mucosal damage in IBD, which is a potential target for IBD treatment (177). Here, OPTN is linked to inflammatory bowel disease.